 |
NICE, the UK government drugs watchdog, has published final guidance recommending that Tysabri should be available on the NHS for people with rapidly evolving, severe, relapsing remitting MS.
The UK MS Society has welcomed the decision, which will benefit nearly 3,000 people with this form of MS.
To read more click on the link below.
Source: UK MS Society
Weblink: click here
|
